Can a new injection calm severe eczema when creams fall short?
NCT ID NCT07765888
First seen Aug 14, 2026 · Last updated Aug 14, 2026
Summary
This study tests whether an investigational drug called tilrekimig, given as injections alongside medicated creams or ointments, can improve moderate-to-severe eczema (atopic dermatitis) in people aged 12 and older. Participants will be randomly assigned to receive either tilrekimig or a placebo (an inactive look-alike) for 24 weeks. The goal is to see if the treatment reduces the severity of eczema and improves quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tilrekimig (also known as PF-07275315), given as subcutaneous injections, combined with medicated creams or ointments
- What this could lead to
- If successful, this could offer a new treatment option for people with moderate-to-severe eczema that isn't well controlled by topical creams alone.
- What could go wrong
- This is a Phase 3 trial, but results are not yet known. The drug may not work better than placebo, and there could be side effects from the injections or the combination therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.